BD and Apax breathe life into respiratory health business, Vyaire Medical
Given Vyaire's annual earnings and the market potential in respiratory diseases and anesthesia, the $500 million price tag seems like a good deal for Apax.
Given Vyaire's annual earnings and the market potential in respiratory diseases and anesthesia, the $500 million price tag seems like a good deal for Apax.